Kamada Ltd. entered into a three-year sales agreement to supply normal source plasma from its Texas-based collection centers to a leading biopharmaceutical company. The agreement is expected to generate approximately $50 million in revenue over the three-year term, with initial commercial sales expected to be recorded in the fourth quarter of 2026. Kamada is a global biopharmaceutical company that develops and markets products for rare and serious conditions.
